Marcia L Gordon

Title: Marcia L. Gordon: Innovator in Monoclonal Antibodies

Introduction

Marcia L. Gordon is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work has implications for diagnosing and treating various immunological disorders.

Latest Patents

Marcia L. Gordon holds a patent for "Monoclonal antibodies specific for different epitopes of human GP39." This invention provides monoclonal antibodies, antigen binding fragments, and recombinant binding proteins that are specific for human gp39. The antibodies target at least eight different epitopes on gp39. The patent also discloses the amino acid sequences of immunoglobulin light and heavy chain variable regions that bind to these epitopes. Furthermore, it includes pharmaceutical compositions comprising these monoclonal antibodies and methods for their use in diagnosing disease states, inhibiting B cell activation, and treating immunological disorders such as autoimmune diseases, allergic responses, organ rejection, and graft-versus-host disease. Additionally, these antibodies can be utilized to image cells expressing gp39, such as tumor cells.

Career Highlights

Marcia L. Gordon is associated with Bristol-Myers Squibb Company, where she has contributed to groundbreaking research in her field. Her innovative work has led to advancements in therapeutic applications and has positioned her as a key figure in biotechnology.

Collaborations

Marcia has collaborated with notable colleagues, including Anthony W. Siadak and Diane L. Hollenbaugh. These collaborations have further enhanced her research and development efforts in monoclonal antibodies.

Conclusion

Marcia L. Gordon's contributions to the field of monoclonal antibodies have paved the way for advancements in diagnosing and treating immunological disorders. Her innovative spirit and dedication to research continue to impact the biotechnology industry positively.